A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
Status:
Active, not recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
E1Z11 is a study to determine whether certain genetic information can predict which breast
cancer patients will discontinue treatment with AIs due to the development of musculoskeletal
symptoms (MSS). Women with stage 1-111 breast cancer who are prescribed the aromatase
inhibitor anastrozole as treatment may join.